Future of ToxicologyIron Chelators and Differing Modes of Action and Toxicity: The Changing Face of Iron Chelation Therapy
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Iron (Fe) chelation therapy was initially designed to alleviate the toxic effects of excess Fe evident in Fe-overload diseases. However, the novel toxicological properties of some Fe chelator-metal complexes have shifted appreciable focus to their application in cancer chemotherapy. Redox-inactive Fe chelator complexes are well suited for the treatment of Fe-overload diseases, whereas Fe chelator complexes with high redox activity have shown promising results as chemotherapeutics against cancer. Within this perspective, we discuss the different modes of action and toxicological profiles of Fe chelators, including analogues of 2-pyridylcarboxaldehyde isonicotinoyl hydrazone, di-2-pyridylketone isonicotinoyl hydrazone, di-2-pyridylketone thiosemicarbazone, and the clinically trialed chelator 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. The potential application of these agents in the changing face of Fe chelation therapy is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Kalinowski and Richardson have recently reviewed synthetic chelators based on various chelating chemical groupings such as catechol, hydroxamate, and hydroxypyridinone, concluding that structures providing hexadentate hydroxypyridinone functionality (an example being deferiprone) have particular promise as bacteriostatic agents in relation to outcompeting siderophores of microbes [49].”
From The utility of iron chelators in the management of inflammatory disorders (2015) · cites this paper as [49]
Citations
Cites
Free Radicals in Biology and Medicine
Land, E. T. (1990) · International Journal of Radiation Biology · doi:10.1080/09553009014552071 · Cited by 4,854
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Thelander, L., & Reichard, P. (1979) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.48.070179.001025 · Cited by 1,167
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Self-citationRichardson, D. R., Sharpe, P. C., Lovejoy, D. B., Senaratne, D., Kalinowski, D. S., Islam, M., & Bernhardt, P. V. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0606342 · Cited by 383
Self-citationLe, N. T. V., & Richardson, D. R. (2004) · Blood · doi:10.1182/blood-2004-05-1866 · Cited by 321
Self-citationFinch, R. A., Liu, M.-C., Cory, A. H., Cory, J. G., & Sartorelli, A. C. (1999) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(98)00017-x · Cited by 223
Chaston, T. B., Lovejoy, D. B., Watts, R., & Richardson, D. R. (2003) · PubMed · Cited by 221
Self-citationChelators at the cancer coalface: Desferrioxamine to Triapine and beyond
Yu, Y., Wong, J., Lovejoy, D. B., Kalinowski, D. S., & Richardson, D. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1954 · Cited by 195
Self-citationWadler, S., Makower, D., Clairmont, C., Lambert, P., Fehn, K., & Sznol, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.158 · Cited by 139
Research works printed but not linked: 28
- Liu Z. D., 2002, Med. Res. Rev., 22, 64
- Lovejoy D. B., 2000, Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasia. Expert Opin. Invest. Drugs 9, 1257−1270
- Olivieri N. F., 1997, Iron-chelating therapy and the treatment of thalassemia. Blood 89, 739−761
- Wong A., 1999, The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 8, 425−430
- Shinar E., 1990, Semin. Hematol., 27, 82
- Kolberg M., 2004, Biochim. Biophys. Acta, 1699, 34
- Thelander L., 1983, Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun. 110, 859−865
- Gao J., 2001, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 98, 842−850.
- Nurtjahja-Tjendraputra E., 2006, Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood, in press
- Armstrong C. M., 2003, Eur. J. Inorg. Chem., 2003
- Wong C. S., 2004, Biochim. Biophys. Acta, 1739, 80
- Richardson D. R., 2001, Biochim. Biophys. Acta, 1536
- Chaston T. B., 2004, Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation. Clin. Cancer Res. 10, 7365−7374
- Sartorelli A. C., 1971, Mechanism of inhibition of ribonucleoside diphosphate reductase by α-(N)-heterocyclic aldehyde thiosemicarbazones. Biochem. Pharmacol. 20, 3119−3123
- Sartorelli A. C., 1967, Inhibition of the growth of sarcoma 180 ascites cells by combinations of inhibitors of nucleic acid biosynthesis and the cupric chelate of kethoxal bis-(thiosemicarbazone). Cancer Res. 27, 1614−1619
- Agrawal K. C., 1978, The chemistry and biological activity of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog. Med. Chem. 15, 321−356
- Yuan J., 2004, Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104, 1450−1458
- Whitnall M., 2006, Proc. Natl. Acad. Sci. U.S.A. 103
- Shao J., 2006, A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol. Cancer. Ther. 5, 586−592
- Cory J. G., 1994, Inhibitors of ribonucleotide reductase: Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem. Pharmacol. 48, 335−344
- Finch R. A., 2000, Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. 59, 983−991
- Shao J., 2004, Cancer Res., 64, 6
- Cooper C. E., 1996, J. Biol. Chem., 271
- Chen C. H., 2002, Eur. J. Cancer, 38, S26
- Yen Y., 2004, A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother. Pharmacol. 54, 331−342
- Liu Z. D., 2002, Coord. Chem. Rev., 232
- Richardson D. R., 1995, The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86, 4295−4306
- Abbreviations AP, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
Cited by
Essential metals in health and disease
Jomova, K., Makova, M., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., Rhodes, C. J., & Valko, M. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110173 · Cited by 1,121
Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
Wondrak, G. T. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2541 · Cited by 462
Yu, Y., Kalinowski, D. S., Kovacevic, Z., Siafakas, A. R., Jansson, P. J., Stefani, C., Lovejoy, D. B., Sharpe, P. C., Bernhardt, P. V., & Richardson, D. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900552r · Cited by 397
Self-citationLignin-derivatives based polymers, blends and composites: A review
Naseem, A., Tabasum, S., Zia, K. M., Zuber, M., Ali, M., & Noreen, A. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.08.030 · Cited by 343
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
“Thiosemicarbazone:Fe complexes cause oxidative stress by the creation of hydroxyl radicals through Fenton chemistry (Kalinowski and Richardson, 2007; Richardson et al., 2006, 2009).”
Metadata
- Authors
- Kalinowski, D. S., & Richardson, D. R.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Richardson, Des R.
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-04-03
- Volume
- 20
- Issue
- 5
- Pages
- 715-720
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W2071434358
- Cited by
- 145
- References
- 15
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 9 · 2019: 9 · 2018: 10 · 2017: 6 · 2016: 11 · 2015: 9 · 2014: 4 · 2013: 3 · 2012: 7
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Research in Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Heavy Metal Exposure and Toxicity
- Keywords
- iron chelators, cancer chemotherapy, redox activity, hydrazone complexes, thiosemicarbazone complexes, iron chelation therapy
- MeSH terms
- Humans, Hydrazones, Iron Chelating Agents, Isoniazid, Pyridines, Pyridoxal, Structure-Activity Relationship, Thiosemicarbazones, Toxicology, Chelation Therapy, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Future of ToxicologyIron Chelators and Differing Modes of Action and Toxicity: The Changing Face of Iron Chelation Therapy. https://app.cochat.ai/papers/10.1021/tx700039c
- The paper
- Kalinowski, D. S., & Richardson, D. R. (2007). Future of ToxicologyIron Chelators and Differing Modes of Action and Toxicity: The Changing Face of Iron Chelation Therapy. Chemical Research in Toxicology. https://doi.org/10.1021/tx700039c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.